Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 6/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | MAT2A | P31153 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424373 | 1.00 | CHRM5 (0.51) | CHRM5IRAK4UBE2MDCUN1D1TAS1R3 | |
| SCHEMBL14424271 | 0.93 | CHRM5 (0.53) | CHRM5IRAK4UBE2MDCUN1D1CHKA | |
| SCHEMBL10114849 | 0.93 | CHRM5 (0.53) | CHRM5IRAK4UBE2MDCUN1D1CHKA | |
| SCHEMBL10114132 | 0.89 | CHRM5 (0.54) | CHRM5IRAK4CHKACHKBIKBKB | |
| SCHEMBL14424265 | 0.89 | CHRM5 (0.54) | CHRM5IRAK4CHKACHKBIKBKB | |
| SCHEMBL17090397 | 0.83 | IRAK4 (0.42) | CHRM5IRAK4UBE2MDCUN1D1TAS1R3 | |
| SCHEMBL13565309 | 0.83 | IRAK4 (0.42) | CHRM5IRAK4UBE2MDCUN1D1TAS1R3 | |
| SCHEMBL10114822 | 0.81 | CHRM5 (0.56) | CHRM5 | |
| SCHEMBL13203868 | 0.81 | CHRM5 (0.54) | CHRM5IRAK4CHKACHKBIKBKB | |
| SCHEMBL10113350 | 0.81 | CHRM5 (0.54) | CHRM5IRAK4CHKACHKBIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | CHRM5 68/4885IRAK4 3822/4885UBE2M 4540/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CHRM5 66/4885IRAK4 3752/4885UBE2M 4634/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | CHRM5 66/4885IRAK4 3753/4885UBE2M 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.